SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 15:42:12 26/06/2024 BST | ||
| 3.16 EUR | -1.86% |
|
| Current month | -1.53% | ||
| 1 month | +0.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 3.16 | -1.86% |
| 25/06/24 | 3.22 | +0.63% |
| 24/06/24 | 3.2 | -2.74% |
| 21/06/24 | 3.29 | -1.20% |
| 20/06/24 | 3.33 | +0.91% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:42 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU3B9A |
| ISIN | DE000VU3B9A5 |
| Date issued | 08/02/2023 |
| Strike | 76.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.32 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.35 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.01 € |
| Spread % | 0.32% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.19
USD
Average target price
53.19
USD
Spread / Average Target
+26.08%
- Stock Market
- Certificates
- Certificat
